RV 6153

Drug Profile

RV 6153

Alternative Names: RV6153

Latest Information Update: 15 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator RespiVert
  • Class Antiasthmatics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase modulators; Phosphotransferase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Asthma
  • Preclinical Chronic obstructive pulmonary disease

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 03 Mar 2016 Respivert terminates a phase I trial for Asthma in United Kingdom (NCT02517359)
  • 01 Jul 2015 Phase-I clinical trials in Asthma in United Kingdom (Inhalation) (NCT02517359)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top